Ichiro Watanabe
Kitasato University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ichiro Watanabe.
Heart and Vessels | 2014
Takeru Nabeta; Takayuki Inomata; Yuichiro Iida; Yuki Ikeda; Miwa Iwamoto; Shunsuke Ishii; Takanori Sato; Ichiro Watanabe; Takashi Naruke; Hisahito Shinagawa; Toshimi Koitabashi; Ichiro Takeuchi; Mototsugu Nishii; Yusuke Inoue; Tohru Izumi
Endomyocardial biopsy (EMB) and late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) imaging performed at baseline are both used to evaluate the extent of myocardial fibrosis. However, no study has directly compared the effectiveness of these diagnostic tools in the prediction of left ventricular reverse remodeling (LVRR) and prognosis in response to therapy in patients with idiopathic dilated cardiomyopathy (IDCM). Seventy-five patients with newly diagnosed IDCM who were undergoing optimal therapy were assessed at baseline using LGE-CMR imaging and EMB; the former measured LGE area and the latter measured collagen volume fraction (CVF) as possible predictive indices of LVRR and cardiac event-free survival. Among all the baseline primary candidate factors with P < 0.2 as per univariate analysis, multivariate analysis indicated that only LGE area was an independent predictor of subsequent LVRR (β = 0.44; 95 % confidence interval (CI) 0.87–2.53; P < 0.001), as indicated by decreasing left ventricular end-systolic volume index over the 1-year follow-up. Kaplan–Meier curves indicated significantly lower cardiac event-free survival rates in patients with LGE at baseline than in patients without (P < 0.01). By contrast, there was no significant difference in prognosis between patients with CVF values above (severe fibrosis) and below (mild fibrosis) the median of 4.9 %. Cox proportional hazard analysis showed that LGE area was an independent predictor of subsequent cardiac events (hazard ratio 1.06; 95 % CI 1.02–1.10; P ≤ 0.01). The degree of myocardial fibrosis estimated by baseline LGE-CMR imaging, but not that estimated by baseline EMB, can predict LVRR and cardiac event-free survival in response to therapy in patients with newly diagnosed IDCM.
Heart and Vessels | 2014
Shunsuke Ishii; Takayuki Inomata; Yuki Ikeda; Takeru Nabeta; Miwa Iwamoto; Ichiro Watanabe; Takashi Naruke; Hisahito Shinagawa; Toshimi Koitabashi; Mototsugu Nishii; Ichiro Takeuchi; Tohru Izumi
Although an increased heart rate (HR) is a strong predictor of poor prognosis in cases of chronic heart failure (HF), the clinical value of HR as a predictor in acute decompensated HF (ADHF) is unclear. Seventy-eight patients with nonischemic dilated cardiomyopathy (NIDCM) with sinus rhythm who were first hospitalized for ADHF from 2002 to 2010 were retrospectively investigated after exclusion of patients with tachycardia-induced cardiomyopathy. The patients were divided into two groups stratified by HR on admission with a median value of 113 beats/min (Group H with HR ≥ 113 beats/min; Group L with HR < 113 beats/min). Despite similar backgrounds, including pharmacotherapy for HF, HR changes responding to titration of β-blocker (BB) therapy and myocardial interstitial fibrosis, left ventricular (LV) ejection fractions improved more significantly 1 year later in Group H than in Group L (57 % ± 11 % vs. 46 % ± 12 %, P < 0.001). Cardiac event-free survival rates were also significantly improved in Group H (P = 0.038). Multiple regression analysis revealed that only the peak HR on admission was an independent predictor of LV reverse remodeling (LVRR) 1 year later (β = 0.396, P = 0.005). High HR on first admission for ADHF is a strong predictor of LVRR, with a better prognosis in the event of NIDCM in response to optimal pharmacotherapy, independent of pre-existing myocardial damage and subsequent HR reduction by BB therapy.
International Heart Journal | 2011
Tomoyoshi Yanagisawa; Takayuki Inomata; Ichiro Watanabe; Emi Maekawa; Tomohiro Mizutani; Hisahito Shinagawa; Toshimi Koitabashi; Ichiro Takeuchi; Tohru Izumi
International Heart Journal | 2011
Emi Maekawa; Takayuki Inomata; Ichiro Watanabe; Tomoyoshi Yanagisawa; Tomohiro Mizutani; Hisahito Shinagawa; Toshimi Koitabashi; Ichiro Takeuchi; Yusuke Inoue; Tohru Izumi
International Heart Journal | 2011
Tomohiro Mizutani; Takayuki Inomata; Ichiro Watanabe; Emi Maekawa; Tomoyoshi Yanagisawa; Hisahito Shinagawa; Toshimi Koitabashi; Ichiro Takeuchi; Tohru Izumi
Journal of Pharmaceutical Health Care and Sciences | 2016
Toshiaki Komatsu; Takayuki Inomata; Ichiro Watanabe; Masahiro Kobayashi; Hideya Kokubun; Junya Ako; Koichiro Atsuda
Journal of Cardiac Failure | 2010
Ichiro Watanabe; Takayuki Inomata; Makoto Nishinari; Shunsuke Ishii; Emi Maekawa; Tomoyoshi Yanagisawa; Tomoyasu Mizutani; Hisahito Shinagawa; Toshimi Koitabasi; Tohru Izumi
Journal of Cardiac Failure | 2012
Takeru Nabeta; Takayuki Inomata; Yuki Ikeda; Takanori Sato; Ichiro Watanabe; Takashi Naruke; Toshimi Koitabashi; Ichiro Takeuchi; Mototsugu Nishii; Tohru Izumi
Journal of Cardiac Failure | 2012
Yuki Ikeda; Takayuki Inomata; Toshimi Koitabashi; Takashi Naruke; Ichiro Watanabe; Shunsuke Isii; Ichirou Takeuchi; Tohru Izumi
Journal of Cardiac Failure | 2012
Miwa Iwamoto; Takayuki Inomata; Shunsuke Ishii; Ichiro Watanabe; Takashi Naruke; Hisahito Shinagawa; Toshimi Koitabashi; Mototsugu Nishii; Ichiro Takeuchi; Toru Izumi